American Society of Clinical Oncology

SHERPA: White

People

  1. Hudis
    Hudis
  2. Modi
    Modi
  3. D'Andrea-Carlino
    D'Andrea-Carlino
  4. Goldfarb
    Goldfarb
  5. Lake
    Lake
  6. Berger
    Berger
  7. Chandarlapaty
    Chandarlapaty
  8. Fornier
    Fornier
  9. Caravella
    Caravella
  10. Covey
    Covey

Groups

  1. Alan and Sandra Gerry Metastasis and Tumor Ecosystems Center (4)
  2. Biostatistics Service (4)
  3. Breast Medicine Service (4)
  4. Department of Medicine (4)
  5. Epidemiology and Biostatistics (4)
  6. Solid Tumor Oncology Division (4)
  7. Survivorship Research (4)
  8. GSK Faculty (3)
  9. Health Outcomes Research Group (3)
  10. Human Oncology and Pathogenesis Program (3)
Search Within
  1. "Biostatistics Service"
  2. "Breast Medicine Service"
  3. "Jose Baselga"
  4. "Maura Dickler"
Formats
  1. Meeting Abstract (3)
  2. Journal Article (1)
Groups
  1. Alan and Sandra Gerry Metastasis and Tumor Ecosystems Center (4)
  2. Biostatistics Service (4)
  3. Breast Medicine Service (4)
  4. Department of Medicine (4)
  5. Epidemiology and Biostatistics (4)
  6. Solid Tumor Oncology Division (4)

More Groups

People
  1. Clifford Hudis (4)
  2. Jose Baselga (4)
  3. Mary Ellen Moynahan (4)
  4. Maura Dickler (4)
  5. Shanu Modi (4)
  6. Diana Lake (3)

More People

Years
  1. 2015 (2)
  2. 2014 (2)
Publications
  1. Journal of Clinical Oncology (4)

Results (4)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Phase I study of LJM716, BYL719, and trastuzumab in patients (pts) with HER2-amplified (HER2+) metastatic breast cancer (MBC)
    Meeting Abstract

    Shah, P. D.; Chandarlapaty, S.; Dickler, M. N.; Ulaner, G.; Zamora, S. J.; Sterlin, V.; Iasonos, A.; Coughlin, C. M.; Morozov, A.; Ero, J.; more...
    Journal of Clinical Oncology (2015)

    Fulltext@MSK | Save
  • Phase II study of paclitaxel given once per week along with trastuzumab and pertuzumab in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer
    Journal Article

    Dang, C.; Iyengar, N.; Datko, F.; D'Andrea, G.; Theodoulou, M.; Dickler, M.; Goldfarb, S.; Lake, D.; Fasano, J.; Fornier, M.; more...
    Journal of Clinical Oncology (2015)

    Fulltext@MSK | Save
  • Phase I trial of daily PI3K alpha inhibitor BYL719 plus letrozole (L) or exemestane (E) for patients (pts) with hormone receptor-positive (HR plus ) metastatic breast cancer (MBC)
    Meeting Abstract

    Shah, P. D.; Modi, S.; Datko, F. M.; Moynahan, M. E.; Zamora, S.; D'Andrea, G.; Lake, D.; Goldfarb, S. B.; Patil, S.; Singh, S.; more...
    Journal of Clinical Oncology (2014)

    Fulltext@MSK | Save
  • Monitoring PIK3CA mutant allele fraction (AF) in cell-free DNA (cfDNA) in metastatic breast cancer (MBC) patients treated with PI3K alpha-inhibitor plus letrozole (L) or exemestane (E)
    Meeting Abstract

    Moynahan, M. E.; Sung, P.; Asham, M.; Zamora, S.; Shah, P. D.; Modi, S.; Lake, D.; D'Andrea, G.; Goldfarb, S. B.; Chandarlapaty, S.; more...
    Journal of Clinical Oncology (2014)

    Fulltext@MSK | Save